Discovering breakthroughs in fibrosis and neurodegeneration
To bring life-changing treatments to patients with fibrotic and neurodegenerative diseases
Blade Therapeutics is a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that impact millions of people worldwide. We are a leader in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses associated with fibrotic and neurodegenerative diseases.
Our focused approach offers the potential to produce disease-modifying, life-saving therapies. Since our founding in 2015, the Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development.
Blade is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases.